Edwards Lifesciences (EW) Projected to Post Earnings on Thursday

Key Points

• Edwards Lifesciences is set to announce its Q3 2025 earnings on Thursday, October 23, with analysts expecting earnings of $0.59 per share and revenue of $1.495 billion.
• In its last quarterly report, the company posted $0.67 EPS and $1.53 billion in revenue, exceeding analysts’ expectations and marking an increase of 11.9% year-over-year.
• Edwards Lifesciences' stock has a consensus rating of "Moderate Buy" and a target price of $87.06 from analysts, despite some recent downgrades from "strong-buy" to "buy" ratings.

Edwards Lifesciences (NYSE:EW - Get Free Report) is expected to announce its Q3 2025 results before the market opens on Thursday, October 23rd. Analysts expect the company to announce earnings of $0.59 per share and revenue of $1.4950 billion for the quarter. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS.Interested persons may visit the the company's upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, October 23, 2025 at 5:30 PM ET.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company had revenue of $1.53 billion for the quarter, compared to analysts' expectations of $1.49 billion. During the same quarter in the previous year, the firm posted $0.70 earnings per share. The firm's quarterly revenue was up 11.9% on a year-over-year basis. On average, analysts expect Edwards Lifesciences to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Edwards Lifesciences Price Performance

EW stock opened at $72.92 on Thursday. The firm has a market cap of $42.81 billion, a P/E ratio of 10.49, a price-to-earnings-growth ratio of 3.52 and a beta of 1.05. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. Edwards Lifesciences has a 1 year low of $64.89 and a 1 year high of $83.00. The stock has a 50-day simple moving average of $77.72 and a 200-day simple moving average of $76.14.

Wall Street Analyst Weigh In

EW has been the subject of several recent research reports. Wall Street Zen downgraded shares of Edwards Lifesciences from a "strong-buy" rating to a "buy" rating in a research report on Monday, September 29th. Oppenheimer lowered shares of Edwards Lifesciences from an "outperform" rating to a "market perform" rating in a report on Wednesday, October 8th. Mizuho lifted their price target on shares of Edwards Lifesciences from $87.00 to $95.00 and gave the stock an "outperform" rating in a research note on Friday, July 25th. Stifel Nicolaus set a $85.00 price objective on shares of Edwards Lifesciences and gave the company a "buy" rating in a research report on Monday, September 22nd. Finally, Morgan Stanley raised their target price on Edwards Lifesciences from $75.00 to $81.00 and gave the company an "equal weight" rating in a research note on Tuesday, July 15th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $87.06.

Insider Activity

In related news, VP Daniel J. Lippis sold 4,114 shares of the business's stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the sale, the vice president directly owned 22,002 shares of the company's stock, valued at $1,748,278.92. The trade was a 15.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Larry L. Wood sold 8,950 shares of the company's stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the sale, the insider owned 206,900 shares in the company, valued at $16,150,614. The trade was a 4.15% decrease in their position. The disclosure for this sale can be found here. 1.29% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Edwards Lifesciences

Institutional investors and hedge funds have recently made changes to their positions in the company. Rakuten Securities Inc. boosted its holdings in Edwards Lifesciences by 413.7% in the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company's stock worth $29,000 after purchasing an additional 302 shares during the period. Geneos Wealth Management Inc. lifted its position in shares of Edwards Lifesciences by 6.4% in the 2nd quarter. Geneos Wealth Management Inc. now owns 7,939 shares of the medical research company's stock worth $621,000 after buying an additional 476 shares during the last quarter. Benjamin Edwards Inc. boosted its holdings in shares of Edwards Lifesciences by 12.0% in the 2nd quarter. Benjamin Edwards Inc. now owns 6,753 shares of the medical research company's stock valued at $528,000 after buying an additional 721 shares during the period. Chapman Financial Group LLC acquired a new position in shares of Edwards Lifesciences in the 2nd quarter valued at about $63,000. Finally, Howland Capital Management LLC grew its position in shares of Edwards Lifesciences by 2.8% during the 2nd quarter. Howland Capital Management LLC now owns 29,936 shares of the medical research company's stock valued at $2,341,000 after buying an additional 816 shares during the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.